Treating atherosclerosis: targeting risk factors should not be the only option.
作者信息
Fibla Montserrat, Hernández-Aguilera Anna, Camps Jordi, Menendez Javier A, Joven Jorge
机构信息
Universitat Rovira i Virgili, Department of Medicine and Surgery, Reus, Spain.
Unitat de Recerca Biomèdica (URB-CRB), Hospital Universitari de Sant Joan, Institut d'Investigació Sanitària Pere Virgili, Reus, Spain.
出版信息
Ann Transl Med. 2018 Nov;6(Suppl 1):S34. doi: 10.21037/atm.2018.09.40.
Abstract
摘要
相似文献
1
Treating atherosclerosis: targeting risk factors should not be the only option.
Ann Transl Med. 2018 Nov;6(Suppl 1):S34. doi: 10.21037/atm.2018.09.40.
2
Comparison of in vivo targeting ability between cRGD and collagen-targeting peptide conjugated nano-carriers for atherosclerosis.
J Control Release. 2018 Jan 10;269:337-346. doi: 10.1016/j.jconrel.2017.11.033. Epub 2017 Nov 22.
4
Role of polymorphonuclear neutrophils in atherosclerosis: current state and future perspectives.
Atherosclerosis. 2010 May;210(1):1-13. doi: 10.1016/j.atherosclerosis.2009.10.028. Epub 2009 Oct 29.
5
Targeting the ubiquitin-proteasome system in atherosclerosis: status quo, challenges, and perspectives.
Antioxid Redox Signal. 2014 Dec 10;21(17):2344-63. doi: 10.1089/ars.2013.5805. Epub 2014 Mar 10.
6
Recent advances on CD4 T cells in atherosclerosis and its implications for therapy.
Eur J Pharmacol. 2017 Dec 5;816:58-66. doi: 10.1016/j.ejphar.2017.04.029. Epub 2017 Apr 28.
7
Is it time to move from treating risk factors of the disease to treating the disease?
Eur Heart J. 2018 Jul 1;39(25):2409-2411. doi: 10.1093/eurheartj/ehy343.
8
Inflammation and beyond: new directions and emerging drugs for treating atherosclerosis.
Expert Opin Emerg Drugs. 2017 Mar;22(1):1-26. doi: 10.1080/14728214.2017.1269743. Epub 2016 Dec 22.
9
Macrophage: A Key Therapeutic Target in Atherosclerosis?
Curr Pharm Des. 2019;25(29):3165-3174. doi: 10.2174/1381612825666190830153056.
10
Cholesterol Homeostasis and Liver X Receptor (LXR) in Atherosclerosis.
Cardiovasc Hematol Disord Drug Targets. 2018;18(1):27-33. doi: 10.2174/1871529X18666180302113713.
引用本文的文献
1
Effect of vasa vasorum in cerebrovascular compensation: 2 case reports.
Ann Transl Med. 2020 Apr;8(7):508. doi: 10.21037/atm.2020.03.77.
本文引用的文献
1
Role of inflammation in the pathogenesis of atherosclerosis and therapeutic interventions.
Atherosclerosis. 2018 Sep;276:98-108. doi: 10.1016/j.atherosclerosis.2018.07.014. Epub 2018 Jul 25.
2
Reversal of coronary atherosclerosis: Role of life style and medical management.
Trends Cardiovasc Med. 2018 Nov;28(8):524-531. doi: 10.1016/j.tcm.2018.05.002. Epub 2018 May 17.
3
Multimorbidity in Older Adults With Cardiovascular Disease.
J Am Coll Cardiol. 2018 May 15;71(19):2149-2161. doi: 10.1016/j.jacc.2018.03.022.
4
Assessment of extracellular matrix-related biomarkers in patients with lower extremity artery disease.
J Vasc Surg. 2018 Oct;68(4):1135-1142.e6. doi: 10.1016/j.jvs.2017.12.071. Epub 2018 Mar 31.
5
Synthetic High-Density Lipoprotein-Mediated Targeted Delivery of Liver X Receptors Agonist Promotes Atherosclerosis Regression.
EBioMedicine. 2018 Feb;28:225-233. doi: 10.1016/j.ebiom.2017.12.021. Epub 2017 Dec 20.
6
The Potential Therapeutic Application of Peptides and Peptidomimetics in Cardiovascular Disease.
Front Pharmacol. 2017 Jan 6;7:526. doi: 10.3389/fphar.2016.00526. eCollection 2016.
7
Designer vaccine nanodiscs for personalized cancer immunotherapy.
Nat Mater. 2017 Apr;16(4):489-496. doi: 10.1038/nmat4822. Epub 2016 Dec 26.
8
The Different Facets of Dyslipidemia and Hypertension in Atherosclerosis.
Curr Atheroscler Rep. 2016 Dec;18(12):82. doi: 10.1007/s11883-016-0632-z.
9
High-Density Lipoproteins: Nature's Multifunctional Nanoparticles.
ACS Nano. 2016 Mar 22;10(3):3015-41. doi: 10.1021/acsnano.5b07522. Epub 2016 Feb 25.
10
So Much Cholesterol: the unrecognized importance of smooth muscle cells in atherosclerotic foam cell formation.
Curr Opin Lipidol. 2016 Apr;27(2):155-61. doi: 10.1097/MOL.0000000000000279.
Zotero 插件